- Home
- EVAX vs FMST Comparison
EVAX vs FMST Comparison
Compare EVAX & FMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- FMST
- Stock Information
- Founded
- EVAX 2008
- FMST 2005
- Country
- EVAX Denmark
- FMST Canada
- Employees
- EVAX 49
- FMST N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- FMST Other Metals and Minerals
- Sector
- EVAX Health Care
- FMST Basic Materials
- Exchange
- EVAX Nasdaq
- FMST Nasdaq
- Market Cap
- EVAX 8.7M
- FMST 15.8M
- IPO Year
- EVAX 2021
- FMST N/A
- Fundamental
- Price
- EVAX $1.46
- FMST $1.48
- Analyst Decision
- EVAX Strong Buy
- FMST
- Analyst Count
- EVAX 2
- FMST 0
- Target Price
- EVAX $11.00
- FMST N/A
- AVG Volume (30 Days)
- EVAX 41.4K
- FMST 14.6K
- Earning Date
- EVAX 10-31-2024
- FMST 01-01-0001
- Dividend Yield
- EVAX N/A
- FMST N/A
- EPS Growth
- EVAX N/A
- FMST N/A
- EPS
- EVAX N/A
- FMST N/A
- Revenue
- EVAX $3,295,000.00
- FMST N/A
- Revenue This Year
- EVAX $4,845.21
- FMST N/A
- Revenue Next Year
- EVAX $30.30
- FMST N/A
- P/E Ratio
- EVAX N/A
- FMST N/A
- Revenue Growth
- EVAX N/A
- FMST N/A
- 52 Week Low
- EVAX $1.28
- FMST $1.35
- 52 Week High
- EVAX $13.61
- FMST $4.25
- Technical
- Relative Strength Index (RSI)
- EVAX 27.04
- FMST 25.00
- Support Level
- EVAX $1.28
- FMST $1.76
- Resistance Level
- EVAX $1.80
- FMST $1.99
- Average True Range (ATR)
- EVAX 0.27
- FMST 0.19
- MACD
- EVAX -0.08
- FMST -0.04
- Stochastic Oscillator
- EVAX 12.16
- FMST 13.54
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.